Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Peter A. Thompson Sells 1,176,332 Shares

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) Director Peter A. Thompson sold 1,176,332 shares of the firm's stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the sale, the director owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corvus Pharmaceuticals Price Performance

Shares of CRVS traded down $0.14 during mid-day trading on Tuesday, reaching $3.86. 1,287,361 shares of the company's stock were exchanged, compared to its average volume of 823,722. Corvus Pharmaceuticals, Inc. has a 52-week low of $1.75 and a 52-week high of $10.00. The stock has a market capitalization of $263.14 million, a PE ratio of -3.94 and a beta of 0.58. The business's fifty day simple moving average is $3.82 and its 200-day simple moving average is $4.26.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.13). Equities research analysts predict that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in CRVS. Nwam LLC lifted its position in shares of Corvus Pharmaceuticals by 54.2% during the 4th quarter. Nwam LLC now owns 15,500 shares of the company's stock valued at $83,000 after acquiring an additional 5,450 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Corvus Pharmaceuticals by 91.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,968 shares of the company's stock valued at $160,000 after purchasing an additional 14,300 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Corvus Pharmaceuticals in the fourth quarter valued at $583,000. American Century Companies Inc. increased its position in shares of Corvus Pharmaceuticals by 140.4% in the fourth quarter. American Century Companies Inc. now owns 43,774 shares of the company's stock valued at $234,000 after buying an additional 25,566 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth $624,000. Hedge funds and other institutional investors own 46.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reissued an "outperform" rating and issued a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Mizuho set a $11.00 price target on Corvus Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.